Loading
Regulation of Appetite and Obesity · Journal article
International Journal of Molecular Sciences · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
Central Maresin-1 administration modulated hypothalamic POMC expression and circulating metabolic hormones in diet-dependent manner in rats, but did not alter body weight, food intake, or energy balance over 7 days. This is an early mechanistic study offering no evidence of therapeutic efficacy on obesity phenotype.
Controlled experimental animal study with factorial design (diet and dose). Male Wistar albino rats; stratified by 12 weeks prior diet exposure (standard or high-fat).. Intervention: Central Maresin-1 (Mar1) administered by continuous intracerebroventricular infusion at 50 ng/kg/day or 100 ng/kg/day for 7 days. Compared with: Untreated control and vehicle-infused control within each diet condition.
In STD-fed rats, 100 ng Mar1 significantly increased serum insulin versus control (p = 0.025) In STD-fed rats, both Mar1 doses significantly increased leptin versus control (p = 0.0003 and p = 0.0091) In STD-fed rats, 50 ng Mar1 significantly increased ghrelin versus control and vehicle (p = 0.0016 and p = 0.0055)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This rat study does not yet support clinical investigation of Maresin-1 for obesity, as it shows no effect on energy intake or body weight despite modulating hypothalamic neuropeptide signalling. The diet-dependent effects warrant mechanistic follow-up but are insufficient to guide clinical practice.
An exploratory mechanistic study in rats using intracerebroventricular infusion; shows diet-dependent effects on hypothalamic neuropeptide expression and circulating hormones, but no behavioural or body weight change over 7 days, limiting evidence of clinical relevance.
As stated by the source record.
Quoted from the source exactly as published.
This rat study does not yet support clinical investigation of Maresin-1 for obesity, as it shows no effect on energy intake or body weight despite modulating hypothalamic neuropeptide signalling. The diet-dependent effects warrant mechanistic follow-up but are insufficient to guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity is associated with hypothalamic dysfunction, including altered arcuate nucleus (ARC) signaling-related impairment of energy homeostasis. However, the central metabolic effects of the specialized pro-resolving mediator Maresin-1 (Mar1) remain unclear. This study investigated whether central Mar1 administration alters ARC agouti-related peptide (AgRP), proopiomelanocortin (POMC), and metabolic hormone profiles in rats under standard diet (STD) and high-fat diet (HFD) conditions. Male Wistar albino rats were fed either an STD or an HFD for 12 weeks and assigned to untreated control, vehicle, 50 ng/kg/day Mar1, or 100 ng/kg/day Mar1 groups within each diet condition. Mar1 was administered by continuous intracerebroventricular infusion for 7 days. Body weight, food intake, serum insulin, leptin, ghrelin levels, and ARC AgRP and POMC expressions were evaluated. Central Mar1 infusion did not alter body weight or food intake. In STD-fed rats, 100 ng Mar1 significantly increased serum insulin compared to control (p = 0.025), both Mar1 doses significantly increased leptin versus control (p = 0.0003 and p = 0.0091, respectively), and 50 ng Mar1 significantly increased ghrelin compared with control and vehicle groups (p = 0.0016 and p = 0.0055, respectively). In HFD-fed rats, Mar1 did not significantly change serum hormone levels, and the difference in ghrelin between the 50 ng Mar1 and vehicle groups did not reach statistical significance (p = 0.051). Mar1 did not alter AgRP expression in the ARC under either diet condition. However, under HFD, 100 ng Mar1 increased POMC expression relative to control, vehicle, and 50 ng Mar1 groups (p = 0.0076, p = 0.0078 and p = 0.0204, respectively). Central Mar1 infusion therefore altered circulating metabolic hormones with no significant diet x treatment interaction, and increased ARC POMC expression under HFD, an effect supported by a significant diet x treatment interaction (p = 0.0091), without changing energy intake or body weight over the 7-day infusion. These findings indicate a diet-dependent modulation of hypothalamic melanocortin tone rather than a significant effect on energy balance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.